Table 2

Effect of intensive treatment on 6-month changes in SF-36 domains

SF-36 domain	CARDERA				TACIT
	Model 1: Unadjusted		Model 2: Adjusted		Model 1: Unadjusted		Model 2: Adjusted
	β (SE)	p Value	β (SE)	p Value	β (SE)	p Value	β (SE)	p Value
PF	7.55 (2.27)	<0.001	7.97 (2.18)	<0.001	8.61 (3.83)	0.026	5.43 (3.62)	0.135
RP	5.52 (3.94)	0.162	7.34 (3.69)	0.047	5.05 (6.28)	0.423	1.55 (5.78)	0.789
BP	7.59 (2.34)	0.001	8.14 (2.20)	<0.001	5.93 (3.29)	0.073	3.97 (2.89)	0.170
GH	4.52 (1.78)	0.011	5.00 (1.68)	0.003	7.38 (2.97)	0.014	4.16 (2.64)	0.117
VT	1.39 (1.86)	0.454	2.60 (1.76)	0.140	7.46 (3.28)	0.024	4.72 (2.91)	0.107
SF	1.86 (2.69)	0.488	4.57 (2.42)	0.060	6.01 (3.94)	0.129	0.11 (3.47)	0.975
RE	−1.51 (4.52)	0.739	4.36 (3.82)	0.254	1.72 (7.72)	0.824	−6.93 (6.25)	0.269
MH	−0.23 (1.77)	0.898	0.66 (1.61)	0.684	1.09 (3.45)	0.753	−2.25 (2.76)	0.415
PCS	3.84 (1.02)	<0.001	3.78 (0.97)	<0.001	3.70 (1.51)	0.015	3.04 (1.42)	0.034
MCS	−1.33 (1.32)	0.316	0.36 (1.16)	0.757	0.85 (2.29)	0.710	−1.99 (1.91)	0.301

Adjusted model includes following covariates: age, gender, disease duration and baseline SF-36 domain/summary score; cDMARD used as treatment reference group in TACIT analysis.
BP, bodily pain; cDMARD, combination disease-modifying antirheumatic drug; GH, general health; MCS, mental component summary; MH, mental health; PCS, physical component summary; PF, physical functioning; RE, role emotional; RP, role physical; SF, social functioning; SF-36, Short-Form 36; VT, vitality.